One strategy involves engineering dual or tandem CAR-T cells, where two distinct CARs (e.g., mesothelin and FRα) are expressed on the same T cell, ensuring that tumor cells with heterogeneous antigen expression remain vulnerable to attack [120]. The gene discussed is MSLN; the disease is neoplasm.